Literature DB >> 8873222

Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans.

T I Edeki1, J A Goldstein, S M de Morais, L Hajiloo, M Butler, P Chapdelaine, G R Wilkinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8873222     DOI： 10.1097/00008571-199608000-00009

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  9 in total

1.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

2.  Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Jing Xu; Susumu Tazuma; Yoko Horikawa; Masuo Nakamura
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

3.  CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.

Authors:  G A Ford; S M Wood; A K Daly
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

4.  Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.

Authors:  Hai-Ling Qiao; Yu-Rong Hu; Xin Tian; Lin-Jing Jia; Na Gao; Li-Rong Zhang; Yu-Zhong Guo
Journal:  Eur J Clin Pharmacol       Date:  2006-01-10       Impact factor: 2.953

5.  Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.

Authors:  H G Xie; R B Kim; C M Stein; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

6.  Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.

Authors:  Hui-Yan Shi; Jin Yan; Wen-Hui Zhu; Guo-Ping Yang; Zhi-Rong Tan; Wei-Hua Wu; Gan Zhou; Xiao-Ping Chen; Dong-Sheng Ouyang
Journal:  Eur J Clin Pharmacol       Date:  2010-07-29       Impact factor: 2.953

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Authors:  J M Hoskins; G M Shenfield; A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

9.  Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.

Authors:  Tao Jiang; Zhengxing Rong; Yiping Xu; Bing Chen; Yifan Xie; Congying Chen; Yang Lu; Yifeng Shen; Huafang Li; Jing Sun; Hongzhuan Chen
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.